|
1
|
Kyle RA and Rajkumar SV: Multiple myeloma.
Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yarde DN, Oliveira V, Mathews L, Wang X,
Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT,
et al: Targeting the Fanconi anemia/BRCA pathway circumvents drug
resistance in multiple myeloma. Cancer Res. 69:9367–9375. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gao M, Kong Y, Yang G, Gao L and Shi J:
Multiple myeloma cancer stem cells. Oncotarget. 7:35466–35477.
2016.PubMed/NCBI
|
|
4
|
Kikuchi J, Koyama D, Wada T, Izumi T,
Hofgaard PO, Bogen B and Furukawa Y: Phosphorylation-mediated EZH2
inactivation promotes drug resistance in multiple myeloma. J Clin
Invest. 125:4375–4390. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meads MB, Fang B, Mathews L, Gemmer J,
Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, et
al: Targeting PYK2 mediates microenvironment-specific cell death in
multiple myeloma. Oncogene. 35:2723–2734. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su N, Wang P and Li Y: Role of
Wnt/b-catenin pathway in inducing autophagy and apoptosis in
multiple myeloma cells. Oncol Lett. 12:4623–4629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abe M, Harada T and Matsumoto T: Concise
review: Defining and targeting myeloma stem cell-like cells. Stem
Cells. 32:1067–1073. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Munshi NC and Anderson KC: New strategies
in the treatment of multiple myeloma. Clin Cancer Res.
19:3337–3344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Y, Shi J, Tolomelli G, Xu H, Xia J,
Wang H, Zhou W, Zhou Y, Das S, Gu Z, et al: RARα2 expression
confers myeloma stem cell features. Blood. 122:1437–1447. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qiang YW, Endo Y, Rubin JS and Rudikoff S:
Wnt signaling in B-cell neoplasia. Oncogene. 22:1536–1545. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui
H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, et al: Targeting
the beta-catenin/TCF transcriptional complex in the treatment of
multiple myeloma. Proc Natl Acad Sci USA. 104:pp. 7516–7521. 2007;
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Derksen PW, Tjin E, Meijer HP, Klok MD,
MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H,
Nusse R, et al: Illegitimate WNT signaling promotes proliferation
of multiple myeloma cells. Proc Natl Acad Sci USA. 101:pp.
6122–6127. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chapman MA, Lawrence MS, Keats JJ,
Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann
GJ, Adli M, et al: Initial genome sequencing and analysis of
multiple myeloma. Nature. 471:467–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beck JW, Saavedra D, Antell GJ and Tejeiro
B: The treatment of pinworm infections in humans (enterobiasis)
with pyrvinium chloride and pyrvinium pamoate. Am J Trop Med Hyg.
8:349–352. 1959. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esumi H, Lu J, Kurashima Y and Hanaoka T:
Antitumor activity of pyrvinium pamoate,
6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium
pamoate salt, showing preferential cytotoxicity during glucose
starvation. Cancer Sci. 95:685–690. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thorne CA, Hanson AJ, Schneider J, Tahinci
E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson
AG, et al: Small-molecule inhibition of Wnt signaling through
activation of casein kinase 1α. Nat Chem Biol. 6:829–836. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomitsuka E, Kita K and Esumi H: The
NADH-fumarate reductase system, a novel mitochondrial energy
metabolism, is a new target for anticancer therapy in tumor
microenvironments. Ann N Y Acad Sci. 1201:44–49. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones JO, Bolton EC, Huang Y, Feau C, Guy
RK, Yamamoto KR, Hann B and Diamond MI: Non-competitive androgen
receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA.
106:pp. 7233–7238. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Tong J, Tang X, Juan J, Cao B,
Hurren R, Chen G, Taylor P, Xu X, Shi CX, et al: The ubiquitin
ligase HERC4 mediates c-Maf ubiquitination and delays the growth of
multiple myeloma xenografts in nude mice. Blood. 127:1676–1686.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin B, Ding K and Pan J: Ponatinib induces
apoptosis in imatinib-resistant human mast cells by
dephosphorylating mutant D816V KIT and silencing b-catenin
signaling. Mol Cancer Ther. 13:1217–1230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin B, Wang C, Li J, Du X, Ding K and Pan
J: Anthelmintic niclosamide disrupts the interplay of p65 and
FOXM1/β-catenin and eradicates leukemia stem cells in chronic
myelogenous leukemia. Clin Cancer Res. 23:789–803. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin Y, Cao Q, Chen C, Du X, Jin B and Pan
J: Tenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in
acute lymphoblastic leukemia (ALL) cells and eliminates ALL
stem/progenitor cells. BMC Cancer. 15:2262015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin Y, Ding K, Wang D, Shen M and Pan J:
Novel thiazole amine class tyrosine kinase inhibitors induce
apoptosis in human mast cells expressing D816V KIT mutation. Cancer
Lett. 353:115–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y,
Du X, Li J, Li P, Ren R and Pan J: Targeting methyltransferase
PRMT5 eliminates leukemia stem cells in chronic myelogenous
leukemia. J Clin Invest. 126:3961–3980. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin Y, Lu Z, Ding K, Li J, Du X, Chen C,
Sun X, Wu Y, Zhou J and Pan J: Antineoplastic mechanisms of
niclosamide in acute myelogenous leukemia stem cells: Inactivation
of the NF-kappaB pathway and generation of reactive oxygen species.
Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smith TC, Kinkel AW, Gryczko CM and Goulet
JR: Absorption of pyrvinium pamoate. Clin Pharmacol Ther.
19:802–806. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goldberg MT: Pyrvinium pamoate lacks in
vivo genotoxicity in the colon. Toxicol Appl Pharmacol. 74:293–295.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishii I, Harada Y and Kasahara T:
Reprofiling a classical anthelmintic, pyrvinium pamoate, as an
anti-cancer drug targeting mitochondrial respiration. Front Oncol.
2:1372012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buchanan RA, Barrow WB, Heffelfinger JC,
Kinkel AW, Smith TC and Turner JL: Pyrvinium pamoate. Clin
Pharmacol Ther. 16:716–719. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saraswati S, Deskins DL, Holt GE and Young
PP: Pyrvinium, a potent small molecule Wnt inhibitor, increases
engraftment and inhibits lineage commitment of mesenchymal stem
cells (MSCs). Wound Repair Regen. 20:185–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li B, Flaveny CA, Giambelli C, Fei DL, Han
L, Hang BI, Bai F, Pei XH, Nose V, Burlingame O, et al: Repurposing
the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic
agent for intestinal polyposis. PLoS One. 9:e1019692014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeng D, Liu M and Pan J: Blocking EZH2
methylation transferase activity by GSK126 decreases stem cell-like
myeloma cells. Oncotarget. 8:3396–3411. 2017.PubMed/NCBI
|
|
33
|
Nanni C, Versari A, Chauvie S, Bertone E,
Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, et
al: Interpretation criteria for FDG PET/CT in multiple myeloma
(IMPeTUs): Final results. IMPeTUs (Italian myeloma criteria for PET
USe). Eur J Nucl Med Mol Imaging. Dec 21–2017.(Epub ahead of of
Nucl Med Mol Imaging, Dec 21, 2017 (Epub ahead of print).
View Article : Google Scholar
|
